BioNotebook: MoFo BioMeter, Galapagos/GSK, Acasti
This article was originally published in Scrip
Executive Summary
Morrison Foerster BioMeter shows early-stage gains; GlaxoSmithKline investigates third indication for Galapagos drug; and Acasti prices $20m offering.